Company: SPRB
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0000950170-25-053945
Chunk: 19

Company: SPRUCE BIOSCIENCES, INC.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1
Chunk 19
---
 product candidates.

•Interim, topline, and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.

•If the market opportunities for tralesinidase alfa, tildacerfont and our other current and future product candidates are smaller than we believe they are, our future revenue may be adversely affected and our business may suffer.

•We currently have no marketing and sales organization and have yet to commercialize a product. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell tralesinidase alfa, tildacerfont and our other current and future product candidates, we may not be able to generate product revenues.

•Unfavorable U.S. and global economic and geopolitical conditions could adversely affect our business, financial condition or results of operations.